Brassard P, Seifert T, Wissenberg M, Jensen PM, Hansen CK, Secher NH. Phenylephrine decreases frontal lobe oxygenation at rest but not during moderately intense exercise. J Appl Physiol 108: 1472-1478. First published March 11, 2010 doi:10.1152/japplphysiol.01206.2009.-Whether sympathetic activity influences cerebral blood flow (CBF) and oxygenation remains controversial. The influence of sympathetic activity on CBF and oxygenation was evaluated by the effect of phenylephrine on middle cerebral artery (MCA) mean flow velocity (Vmean) and the nearinfrared spectroscopy-derived frontal lobe oxygenation (Sc O 2 ) at rest and during exercise. At rest, nine healthy male subjects received bolus injections of phenylephrine (0.1, 0.25, and 0.4 mg), and changes in mean arterial pressure (MAP), MCA Vmean, internal jugular venous O2 saturation (SjvO 2 ), ScO 2 , and arterial PCO2 (PaCO 2 ) were measured and the cerebral metabolic rate for O 2 (CMRO 2 ) was calculated. In randomized order, a bolus of saline or 0.3 mg of phenylephrine was then injected during semisupine cycling, eliciting a low (ϳ110 beats/ min) or a high (ϳ150 beats/min) heart rate. At rest, MAP and MCA Vmean increased ϳ20% (P Ͻ 0.001) and ϳ10% (P Ͻ 0.001 for 0.25 mg of phenylephrine and P Ͻ 0.05 for 0.4 mg of phenylephrine), respectively. Sc O 2 then decreased ϳ7% (P Ͻ 0.001). Phenylephrine had no effect on SjvO 2 , PaCO 2 , or CMRO 2 . MAP increased after the administration of phenylephrine during low-intensity exercise (ϳ15%), but this was attenuated (ϳ10%) during high-intensity exercise (P Ͻ 0.001). The reduction in Sc O 2 after administration of phenylephrine was attenuated during low-intensity exercise (Ϫ5%, P Ͻ 0.001) and abolished during high-intensity exercise (Ϫ3%, P ϭ not significant), where PaCO 2 decreased 7% (P Ͻ 0.05) and CMRO 2 increased 17% (P Ͻ 0.05). These results suggest that the administration of phenylephrine reduced ScO 2 but that the increased cerebral metabolism needed for moderately intense exercise eliminated that effect. cerebral oxygenation; sympathetic activity; exercise ARTERIAL PRESSURE, METABOLIC activity of the brain, and arterial gas tensions are determinants of cerebral blood flow (CBF), but whether sympathetic activity also influences CBF and cerebral oxygenation remains debated (45, 48) . The cerebral circulation is richly supplied by perivascular adrenergic nerves (12), and smooth muscle cells in the arterioles have ␣-and ␤-adrenergic receptors (11). Sympathetic nerve stimulation constricts cerebral arteries, arterioles, and veins (2, 13, 50) and may protect the brain during acute increases in arterial pressure (3, 14) . For example, cerebral sympathetic activity increases during rapid eye movement sleep, when surges of arterial pressure are observed (7). Biochemical evidence suggests that sympathetic nerve activity influences CBF in humans (30), but it exerts only a minor influence on CBF compared with its role on many other regions of the circulation. While evaluating the impact of arterial pressure changes on CBF velocity and cerebral oxygenation, Lucas et al. (27) reported an increase of middle cerebral artery (MCA) mean flow velocity (V mean ) but a lowering of near-infrared spectroscopy (NIRS)-derived frontal lobe oxygenation (Sc O 2 ) with stepwise increase in arterial pressure. As demonstrated for skeletal muscles, flow is balanced by the metabolic demand of the tissue and sympathetic activity (41). Thus, vasodilatation induced by the high metabolic rate of the brain might counteract the ability of sympathetic nerves to elicit vasoconstriction and reduce CBF and Sc O 2 .
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Phenylephrine and norepinephrine bind to ␣-adrenergic receptors, leading to an increase in mean arterial pressure (MAP) through an elevation in total peripheral resistance (TPR), and cardiac output (CO) is usually lowered or does not increase (4, 31) . However, these drugs are reported to have no impact on CBF (33, 38) or to induce only a small reduction in CBF (24) . Yet continuous infusion of increasing doses of norepinephrine reduces MCA V mean and cerebral oxygenation, characterized by Sc O 2 and internal jugular venous O 2 saturation (Sjv O 2 ) (4). In addition, the utilization of phenylephrine to correct anesthesia-induced hypotension (MAP Ͻ 60 mmHg) reduces Sc O 2 (31) . On the other hand, ephedrine, which stimulates ␣-and ␤-adrenergic receptors directly and indirectly by promoting endogenous release of norepinephrine, maintains Sc O 2 , apparently through an increase in CO (31) .
According to the available literature, the influence of sympathetic nervous activation with phenylephrine on MCA V mean and Sc O 2 is unclear. While increasing arterial pressure with phenylephrine does not seem to reduce CBF (9, 23, 26, 39, 40, 46) , others report an increase in MCA V mean combined with a reduction in Sc O 2 (27) . Although the high metabolic rate of the brain may influence the capacity of the sympathetic nerves to induce vasoconstriction, cerebral metabolic rate for O 2 (CMR O 2 ) has not been evaluated in these studies. Also, no data are available on the impact of stimulating the sympathetic nervous system on MCA V mean and Sc O 2 during exercise, a condition associated with increased CMR O 2 (42) . Within this context, this study evaluated whether phenylephrine affects MCA V mean and Sc O 2 at rest and whether the response is attenuated or eliminated during exercise of increasing intensity as the CMR O 2 increases (42).
METHODS
Nine healthy male subjects (mean Ϯ SD: 23 Ϯ 5 yr, 1.84 Ϯ 0.09 m, and 77 Ϯ 6 kg) participated in the study after providing written informed consent as approved by the regional ethics committee (H-A-2008-056) according to the principles established in the Declara-tion of Helsinki. The subjects did not suffer from any medical conditions, nor were they taking any medications. No restriction on physical activity prior to the study was imposed on the subjects, but they were asked to have a light breakfast before visiting the laboratory.
Catheterization. Upon arrival to the laboratory, the subjects were placed on a hospital bed tilted slightly head-down. Under local anesthesia (2% lidocaine) and guided by ultrasound, a catheter (1.6 mm; model ES-04706, Arrow International) was inserted retrograde in the right internal jugular vein and advanced to its bulb. A second catheter (1.1 mm) was inserted in the left brachial artery and a third catheter (0.7 mm) in the left subclavian vein through an arm vein for the administration of phenylephrine. After catheterization, the subjects were placed supine, and they rested for 1 h to offset the nociceptive stimuli associated with catheterization.
Measurements. (17) . With increasing distance between the emitter and the optodes, light penetrates deeper into the tissues, and with evaluation of absorption at two distances (spatial resolution), absorption in deep tissue, i.e., in the brain, is recorded. Values reported for ScO 2 account predominantly for hemoglobin oxygenation in the frontal cortex, and the NIRS-derived cerebral oxygenation follows the estimated cerebral capillary O2 saturation (36) . The optodes were attached as high as possible on the forehead to avoid the frontal sinuses, and they were covered for protection from external light.
MCA Vmean was monitored through the posterior temporal ultrasound window with transcranial Doppler sonography (Multidop X, DWL, Sipplingen, Germany) using a 2-MHz probe at a depth of 45-55 mm (1) . After the optimal signal-to-noise ratio was obtained, the probe was fixed by adhesive ultrasonic gel (Tensive, Parker Laboratories, Orange, NJ) and secured by a headband. MCA Vmean was calculated from the integral of the maximal-frequency Doppler shifts over one heartbeat by the same operator, and at rest and during exercise, determination of MCA Vmean has a coefficient of variation of ϳ5% (34) .
Hemodynamic monitoring included recording of MAP, heart rate (HR), stroke volume (SV), and thus CO. MAP was measured through a transducer (Edwards Life Sciences, Irvine, CA) placed at the level of the heart and connected to a monitor (Dialogue-2000, IBC-Danica Electronic) with sampling at 100 Hz (Di-720, Dataq) for offline analysis of HR and CO. Beat-to-beat SV was estimated from the arterial pressure wave according to the Modelflow method (52) . Integrating the aortic flow waveform per beat provides left ventricular SV (Beatscope, FMS, Amsterdam, The Netherlands). This derived CO has been successfully validated against a thermodilution estimate of CO during a deliberate reduction in central blood volume induced by head-up tilt and the upright position in healthy subjects (18) , during cardiac surgery and liver transplantation (21, 31) , and in intensive care medicine (22) , as well as against Doppler echocardiography during exercise (47) .
Arterial and internal jugular venous blood samples were obtained simultaneously at baseline and 1, 2, and 15 min after bolus injection of saline or phenylephrine at rest and 1, 2, and 10 min after bolus injection of saline or phenylephrine during exercise. Blood samples were purged of any air bubbles and immediately analyzed for O2, SjvO 2 , and arterial PCO2 (PaCO 2 ) using a blood gas analyzer (ABL 725, Radiometer, Copenhagen, Denmark).
Rest. After 1 h of recovery from catheterization, subjects received an intravenous bolus injection of saline (ϳ5 ml) and three ϳ5-ml doses of phenylephrine (0.1, 0.25, and 0.4 mg) separated by 20 min, and variables were monitored for 15 min. Arterial and internal jugular venous catheterization provided concentration differences for O2. CMRO 2 was derived from the arterial-venous difference for O2 with a resting global CBF taken as 46 ml·100 g Ϫ1 ·min Ϫ1 (29) adjusted to changes in MCA Vmean, with the assumption of a constant vessel diameter (43) . O2, SjvO 2 , and PaCO 2 were measured at baseline and 1, 2, and 15 min after the bolus of saline or phenylephrine. The periods of interest for which data are presented are as follows: 1) at baseline, 2) at the highest MAP after drug administration, 3) at the lowest Sc O 2 within 10 min following the highest MAP, and 4) upon return of ScO 2 to baseline.
Exercise. At 30 min following the experimental protocol at rest, a bolus of saline or 0.3 mg of phenylephrine was injected, in a randomized order, during semisupine cycling at a low (HR ϳ110 beats/min) or a high (HR ϳ150 beats/min) exercise intensity. CMR O 2 is unchanged during low-intensity exercise but increases when the workload is moderately intense (42) . The subjects cycled for 5 min to reach the target steady-state HR. Thereafter, saline or phenylephrine was administered, and the subjects continued to cycle for 10 min. The parameters determined at rest were evaluated during exercise, and data are similarly presented. Each variable represents the mean of the last 3-5 s for each period of interest.
Statistical analysis. A two-way ANOVA on repeated measures at rest [time ‫ء‬ condition (saline or phenylephrine)] and three-way ANOVA with repeated measures during exercise [time ‫ء‬ condition (saline or phenylephrine) ‫ء‬ mode (exercise at 110 beats/min vs. exercise at 150 beats/min)] were performed. Results are presented as means Ϯ SD for data normally distributed or as medians (range), and P Ͻ 0.05 was considered statistically significant by using Sigmastat (SPSS, Chicago, IL) and SAS version 9.1 (SAS Institute, Cary, NC). 
RESULTS
Rest. At rest, MAP increased ϳ20% with augmenting doses of phenylephrine, which was greater than the changes observed with the bolus of saline (P Ͻ 0.001). The highest MAP achieved with the administration of the drug was reached after 32 Ϯ 9, 42 Ϯ 22, and 45 Ϯ 14 s for 0.1, 0.25, and 0.4 mg of phenylephrine, respectively. The increase in MAP was accounted for by an elevation in TPR (by ϳ60%, P Ͻ 0.001) as CO was decreased (Table 1, Fig. 1 ). The reduction in CO was the consequence of a lowering in HR, phenylephrine having no impact on SV, although pulse pressure increased with the highest dose of the drug (P Ͻ 0.05). At the maximal impact of the drug, MCA V mean increased by ϳ10% with 0.25 and 0.4 mg of phenylephrine (P Ͻ 0.001 for 0.25 mg and P Ͻ 0.05 for 0.4 mg), but Sc O 2 was decreased by ϳ7% with increasing doses (P Ͻ 0.001). (Table 2) .
Exercise. Compared with saline, MAP also increased after the administration of phenylephrine during low-intensity exercise (ϳ15%), but this was attenuated (to ϳ10%) during highintensity exercise (P Ͻ 0.001; Table 3 , Fig. 2 ). Since CO was reduced by phenylephrine (P Ͻ 0.05), TPR increased by 34% during low-intensity exercise and by 24% during high-intensity exercise (P Ͻ 0.05). HR was also reduced by phenylephrine compared with saline at both exercise intensities, but the reduction in HR was attenuated during high-intensity exercise (Ϫ10% vs. Ϫ2%, P Ͻ 0.01). The reduction in Sc O 2 following phenylephrine administration during low-intensity exercise (Ϫ5%, P Ͻ 0.001 vs. saline) was lost during high-intensity exercise (Ϫ3%, P ϭ not significant vs. saline). There were no differences in pulse pressure, SV, or MCA V mean after the administration of phenylephrine compared with saline during exercise. Phenylephrine had no influence on Sjv O 2 or CMR O 2 , and while the latter remained unaffected by low-intensity exercise, it increased by 17% (P Ͻ 0.05) during high-intensity exercise. Phenylephrine also had no influence on Pa CO 2 during low-intensity exercise but reduced Pa CO 2 by ϳ7% during high-intensity exercise (P Ͻ 0.05).
DISCUSSION
Stimulation of sympathetic activity by the administration of phenylephrine decreased Sc O 2 in healthy subjects, but exercise of increasing intensity abolished the extent of these changes in regional cerebral oxygenation, possibly as the result of an increase in CMR O 2 . This was the case, although there was a reduction in Pa CO 2 with administration of phenylephrine at the highest workload. These data support the hypothesis that cerebral oxygenation is influenced by sympathetic activity but that this influence is attenuated or lost as CMR O 2 increases during exercise. Stimulation of ␣-adrenergic activity by phenylephrine has not been associated with a reduction in CBF (9, 23, 26, 39, 40, 46) . However, CMR O 2 was not evaluated in these studies, and no exercise data are available. Lucas et al. (27) recently reported an increase in MCA V mean and a lowering of Sc O 2 with a phenylephrine-induced stepwise increase in arterial pressure, which support the present findings. The are several possible explanations for the reduction of Sc O 2 with phenylephrine. The administration of phenylephrine reduced CO (10, 15) as a consequence of a baroreflex-mediated reduction in HR induced by the increase in arterial pressure. An association seems to exist between changes in CO, CBF, and cerebral oxygenation with different physiological stimuli. For example, when CO is reduced in the upright position, both MCA V mean and Sc O 2 decrease, although blood pressure at the level of the brain remains relatively constant (49) . Also during exercise, there is a direct relationship between the increase in MCA V mean and CO in cardiac patients (20) , and increases in CO and MCA V mean are attenuated during exercise following the administration of ␤-adrenergic blocking agents (25) ; the attenuation of MCA V mean is eliminated by regional anesthesia of the sympathetic nerves to the brain (19) . Furthermore, manipulation of CO by administration of albumin vs. lower body negative pressure during exercise is transmitted to a parallel change in MCA V mean (32). ). While Lucas et al. (27) also reported an elevation in MCA V mean with phenylephrine infusion, Sc O 2 was lowered. We interpret the reduction in Sc O 2 as a reflection of a reduction in regional cerebral perfusion and the increase in MCA V mean as a direct effect on the artery by the drug. The administration of phenylephrine may induce changes in small cerebral arterioles, i.e., vasoconstriction, transiently increasing MCA V mean (not CBF). However, this vasoconstriction may eventually reduce Sc O 2 as in the present study. In addition, despite the fact that phenylephrine does not seem to cross an intact blood-brain barrier (33), pharmacologically induced hypertension may have affected the blood-brain barrier (28) . The increase in arterial pressure induced by the bolus of phenylephrine may also have stimulated the superior cervical ganglia, leading to cerebral vasoconstriction (6) . Thus the combination of a reduction in CO, a direct effect of phenylephrine on the vessels, and a cerebral response to an increase in perfusion pressure could contribute to restrain cerebral oxygenation.
We used exercise to modulate the influence of phenylephrine on Sc O 2 . We were inspired by the finding that, for skeletal muscles, there is a metabolic restraint, sympatholysis, on the ability of the sympathetic system to cause vasoconstriction during exercise (37) . Such sympatholysis was evidenced by an important effect of phenylephrine on TPR at rest but, to a lesser degree, during exercise. Similarly, the reduction in Sc O 2 by phenylephrine at rest and during low-intensity exercise was abolished during moderately high-intensity exercise, apparently associated with an increase in CMR O 2 , but other manifestations associated with intense exercise should be considered. For example, increased body temperature is associated with an attenuated vasoconstrictor responsiveness to phenylephrine-induced elevation in arterial pressure in humans (8) . Also, high-intensity exercise may be associated with a hyperventilation-induced reduction in Pa CO 2 , lowering CBF (51) . Yet, even with a lowering of Pa CO 2 , phenylephrine was unable to affect Sc O 2 at the highest exercise intensity.
In the absence of a change in arterial O 2 content, hemoglobin concentration, and CMR O 2 , a reduction in Sjv O 2 would represent a reduction in global cerebral oxygenation. Our data showed no influence of phenylephrine on Sjv O 2 . However, we sampled blood at 1 and 2 min after the bolus of phenylephrine and not at the maximal effect of the drug or the lowest Sc O 2 encountered after the highest MAP. Although it might be that phenylephrine does not influence global cerebral oxygenation, the absence of a reduction in Sjv O 2 may represent a sampling problem. Furthermore, the acute exposure to phenylephrine we used may have been insufficient to influence global cerebral oxygenation. Infusion of norepinephrine decreases Sc O 2 , Sjv O 2 , and MCA V mean in healthy subjects (4) , suggesting that an infusion, rather than a bolus injection, is needed to affect Sjv O 2 . The reduction in Sc O 2 could also be related to decreased skin blood flow measured in the frontal area by NIRS with phenylephrine. However, if that were the case, we would expect a similar effect during exercise. Furthermore, we used spatially resolved NIRS, i.e., two detecting optodes were placed at different distances from the transmitting optodes, such that the signal reflects cerebral, rather than skin and bone, hemoglobin saturation (16, 36) . Nevertheless, an evaluation of CBF by positron emission tomography or magnetic resonance is needed to confirm an effect of phenylephrine on CBF (5, 35) . Finally, CMR O 2 may be overestimated, should MCA diameter be directly or indirectly reduced by phenylephrine.
Conclusion. The administration of phenylephrine reduced Sc O 2 , but increasing CMR O 2 during moderately intense exercise may have abolished that effect, despite Pa CO 2 being lowered. We interpret the lack of an effect of phenylephrine on Sc O 2 during exercise as supporting a balance between cerebral metabolism and a sympathetic restraint on blood flow. A restraint in cerebral oxygenation by phenylephrine could be established directly through a pharmacological effect or a reflex increase in cerebral vascular resistance triggered by the elevation in arterial pressure, eventually supported by a lowered CO.
